Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Cytosorbents (CTSO) Restructuring Costs (2024 - 2025)

Cytosorbents (CTSO) has disclosed Restructuring Costs for 2 consecutive years, with $6.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Restructuring Costs rose 10.4% year-over-year to $6.9 million, compared with a TTM value of $24.7 million through Sep 2025, changed N/A, and an annual FY2024 reading of $23.2 million, down 8.61% over the prior year.
  • Restructuring Costs was $6.9 million for Q3 2025 at Cytosorbents, down from $7.1 million in the prior quarter.
  • Across five years, Restructuring Costs topped out at $7.1 million in Q2 2025 and bottomed at $3.9 million in Q4 2024.